Timeline
AstraZeneca
AstraZeneca prices €2.55bn four-tranche bond offering
AstraZeneca halts Phase III lung cancer trial after data review
AstraZeneca's Tagrisso combo hits survival goals in lung cancer trial
AstraZeneca shares fall on reports of Bristol Myers merger talks
AstraZeneca's Datroway wins EU approval for breast cancer
Broker pitches Sell on AstraZeneca, sees steep downside
AstraZeneca's Ultomiris misses primary goal in adult transplant complication trial
AstraZeneca's Sone-Ve hits survival goal in gastric cancer trial
AstraZeneca lifts H1 profit as oncology offsets Farxiga decline
AstraZeneca wins EU approval for camizestrant breast cancer combination
AstraZeneca licenses lung cancer drug for up to $1.5bn
DB repeats Sell rating on AstraZeneca on Wainua trial miss
AstraZeneca and Ionis ATTR-CM trial fails primary endpoint
AstraZeneca's Datroway wins EU approval recommendation for first-line triple-negative breast cancer
AstraZeneca's Truqap approved in US as targeted treatment for prostate cancer
AstraZeneca wins US approval for Imfinzi in early high‑risk bladder cancer
AstraZeneca says FDA extends decision date for camizestrant, allowing extra data review
AstraZeneca wins CHMP backing for Enhertu tumour‑agnostic approval
Broker calls AstraZeneca pipeline news “frenetic”, repeats Sell rating
AstraZeneca secures US approval for blood pressure drug Baxfendy
AstraZeneca's breast cancer drug Enhertu cleared by FDA
AstraZeneca says Imfinzi plus enfortumab vedotin improves survival in muscle‑invasive bladder cancer
AstraZeneca's Truqap recommended by FDA advisory panel for a form of prostate cancer
AstraZeneca fails to win FDA advisory backing for camizestrant
AstraZeneca repeats 2026 guidance as Q1 revenue rises 8%
AstraZeneca wins US approval for Breztri in asthma
AstraZeneca wins US approval for once-weekly Saphnelo self-injection
AstraZeneca's Ultomiris meets primary endpoint in IgAN Phase III
AstraZeneca reports tozorakimab cuts COPD exacerbations in Phase III MIRANDA
More in Pharma
Shield Therapeutics takes full US control of ACCRUFeR
The iron deficiency specialist will absorb its co-commercialisation partner's sales force and retain all US gross profit from ACCRUFeR, paying Viatris a royalty instead of a profit share.